Search

Study was conducted on the electrochemical method of preparing colloidal silver at low DC voltage. A natural stabilizer was used as a carob bean gum from the carob bean. Using a UV-Vis spectrophotometer and a transmission electron microscope (TEM), colloidal silver (silver nanoparticles) was characterized. It is possible to produce colloidal silver of satisfactory quality by means of this electrochemical method. Silver nanoparticles have exhibited surface plasmon resonance as determined by UV-vis analysis. Based on the TEM analysis, the silver nanoparticles appear to be spherical except in sample E1, where they appear rod-shaped and micrometer-sized. Other three samples had particle sizes ranging from 23–52 nm. In a qualitative analysis of colloidal silver solutions, two types of antibacterial activity were observed. At all dilutions, some colloidal solutions showed better antibacterial activity against gram-positive bacteria (S. aureus, S. pyogenes, E. faecalis) while others displayed better antibacterial activity against gram-negative bacteria (S. enteridis, P. aeruginosa, E. coli).

Study was conducted on the electrochemical method of preparing colloidal silver at low DC voltage. A natural stabilizer was used as a carob bean gum from the carob bean. Using a UV-Vis spectrophotometer and a transmission electron microscope (TEM), colloidal silver (silver nanoparticles) was characterized. It is possible to produce colloidal silver of satisfactory quality by means of this electrochemical method. Silver nanoparticles have exhibited surface plasmon resonance as determined by UV-vis analysis. Based on the TEM analysis, the silver nanoparticles appear to be spherical except in sample E1, where they appear rod-shaped and micrometer-sized. Other three samples had particle sizes ranging from 23–52 nm. In a qualitative analysis of colloidal silver solutions, two types of antibacterial activity were observed. At all dilutions, some colloidal solutions showed better antibacterial activity against gram-positive bacteria (S. aureus, S. pyogenes, E. faecalis) while others displayed better antibacterial activity against gram-negative bacteria (S. enteridis, P. aeruginosa, E. coli). [ABSTRACT FROM AUTHOR]

Abstract Polysaccharides in carob fruit, including carob bean gum (also known as carob gum, locust bean gum) and carob fiber, are widely used in industries such as food, pharmaceuticals, paper, textile, oil well drilling and cosmetics. Carob bean gum is a galactomannan obtained from the seed endosperm of carob tree and the fiber is obtained by removing most of soluble carbohydrates in carob pulp by water extraction. Both the gum and fiber are beneficial to health for many diseases such as diabetes, bowel movements, heart disease and colon cancer. This article reviewed the composition, properties, food applications and health benefits of polysaccharides from carob fruit.

Abstract Following a request from European Commission, the EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) provides a scientific opinion re‐evaluating the safety of locust bean gum (E 410) as a food additive. Locust bean gum (E 410) is an authorised food additive in the EU. Locust bean gum (E 410) as specified in the Commission Regulation (EU) No 231/2012 is derived from the ground endosperm of the seeds of the strains of carob tree, Ceratonia siliqua (L.) Taub. (Family Leguminosae). An acceptable daily intake (ADI) ‘not specified’ was allocated by the Joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives (JECFA) in 1981. Although not evaluated by the Scientific Committee for Food (SCF), it was accepted by the SCF in 1991 for use in weaning food, and in 1994, in infant formulae for special medical purposes. Locust bean gum is practically undigested, not absorbed intact, but significantly fermented by enteric bacteria in humans. No adverse effects were reported in 90‐day toxicity and carcinogenicity studies in rodents at the highest doses tested and there was no concern with respect to the genotoxicity and to reproductive and developmental toxicity of locust bean gum (E 410). The Panel concluded that there is no need for a numerical ADI for locust bean gum (E 410), and that there is no safety concern for the general population at the refined exposure assessment for its reported uses as a food additive. However, infants and young children consuming foods for special medical purposes may show a higher susceptibility to gastrointestinal effects of locust bean gum due to their underlying medical condition. The Panel concluded that the available data do not allow an adequate assessment of the safety of locust bean gum (E 410) in these foods for infants and young children.

Following a request from European Commission, the EFSA Panel on Food Additives and Nutrient Sources added to Food ( ANS) provides a scientific opinion re-evaluating the safety of locust bean gum (E 410) as a food additive. Locust bean gum (E 410) is an authorised food additive in the EU. Locust bean gum (E 410) as specified in the Commission Regulation ( EU) No 231/2012 is derived from the ground endosperm of the seeds of the strains of carob tree, Ceratonia siliqua (L.) Taub. (Family Leguminosae). An acceptable daily intake ( ADI) 'not specified' was allocated by the Joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives ( JECFA) in 1981. Although not evaluated by the Scientific Committee for Food ( SCF), it was accepted by the SCF in 1991 for use in weaning food, and in 1994, in infant formulae for special medical purposes. Locust bean gum is practically undigested, not absorbed intact, but significantly fermented by enteric bacteria in humans. No adverse effects were reported in 90-day toxicity and carcinogenicity studies in rodents at the highest doses tested and there was no concern with respect to the genotoxicity and to reproductive and developmental toxicity of locust bean gum (E 410). The Panel concluded that there is no need for a numerical ADI for locust bean gum (E 410), and that there is no safety concern for the general population at the refined exposure assessment for its reported uses as a food additive. However, infants and young children consuming foods for special medical purposes may show a higher susceptibility to gastrointestinal effects of locust bean gum due to their underlying medical condition. The Panel concluded that the available data do not allow an adequate assessment of the safety of locust bean gum (E 410) in these foods for infants and young children. [ABSTRACT FROM AUTHOR]

Thickening agents, such as carob bean gum or galactomannan, have been successfully administered for the treatment of gastro esophageal reflux in infants. To study the effect of carob bean gum on gastric emptying and to symptoms of regurgitation, we recruited 20 full term Thai infants (mean age 13.4 ± 7 week; mean body weight = 4943 ± 1272gm) without pathological gastroesophageal reflux. Initially, we determined halftime gastric emptying (T 1/2 GET) by Tc99m radioscintigraphy method (mean T 1/2 GET = 116.1 ±72 mm) in infants consuming standard infant cow's milk formula for 2 weeks. Afterwards, carob bean infant formula was given for 2-4 weeks and weight gain, vomiting symptoms, night cough, colic, flatus, defaecation character and T 1/2 GET were assessed. There were statistically significant improvements in symptoms of vomiting (a smaller quantity P<0.00l and frequency of vomiting P < 0.0001) and improvements in weight gain per week (W1 = 121.2 + 106.9gm, W2 221.3 + 136.1gm; P = 0.005) when infants consumed the carob bean formula. However, there was no significance difference in gastric emptying half time (GET1 = 116.1 + 72, GET2 = 148.5 + 130.9; P= 0.154). In conclusion, carob bean gum, as a thickening agent, improves the clinical symptoms of regurgitating infants, but does not significantly alter the gastric emptying physiology. [ABSTRACT FROM AUTHOR]

Aim: To examine the effect of carob-bean gum (CBG) thickened-formulas on reflux and tolerance indices in infants with gastro-esophageal reflux (GER)., Methods: Fifty-six eligible infants (1-6 mo old) were randomly allocated to receive for two weeks a formula with either 0.33 g/100 mL (Formula A) or 0.45 g/100 mL (Formula B) of cold soluble CBG galactomannans respectively, or a formula with 0.45 g/100 mL of hot soluble CBG galactomannans (Formula C). No control group receiving standard formula was included in the study. Data on the following indices were obtained both at baseline and follow-up from all study participants: 24 h esophageal pH monitoring indices, anthropometrical indices (i.e., body weight and length) and tolerance indices (i.e., frequency of colics; type and frequency of defecations). From the eligible infants, forty seven were included in an intention-to-treat analysis to examine the effects of the two-week trial on esophageal 24 h pH monitoring, growth and tolerance indices. Repeated Measures ANOVA was used to examine the research hypothesis., Results: Regarding changes in 24 h pH monitoring indices, significant decreases from baseline to follow-up were observed in the "Boix Ochoa Score" (i.e., an index of esophageal acid exposure), in the total number of visible refluxes and in all symptoms related indices due to acid reflux only for infants provided with Formula A, while no significant changes were observed for infants provided with Formulas B and C. In addition, the significant decreases observed in two symptoms related pH monitoring indices (i.e., "Symptom index for reflux" and "Percentage of all reflux") for infants provided with Formula A were also found to differentiate significantly compared to the changes observed in the other two groups (P = 0.048 and P = 0.014 respectively). Concerning changes in anthropometric indices, body weight significantly increased among infants provided with Formulas A and C, but not for infants provided with Formula B. As far as tolerance indices were concerned, the numbers of total and diarrheic defecations increased significantly only in infants provided with Formula B and these changes were significantly higher compared to the decreases observed in infants fed with Formulas A and C (P = 0.003 and P = 0.015 respectively. Lastly the number of colics significantly decreased in all infants, irrespective of the tested formula., Conclusion: Formula A (i.e., 0.33 g/100 mL of cold galactomannans) was effective in reducing certain pH-monitoring indices of uncomplicated GER, increased body weight and was well-tolerated by infants.